Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What can be learned from the levormeloxifene experience?

Pernille Ravn1, Therese F Nielsen, Claus Christiansen

  • 1Center for Clinical and Basic Research AIS, Ballerup, Denmark. pernille.ravn@ouh.fyns-amt.dk

Acta Obstetricia Et Gynecologica Scandinavica
|March 15, 2006
PubMed
Summary

Levormeloxifene showed promise in animal models and early human trials for preventing postmenopausal bone loss. However, its development was halted due to similar efficacy across doses and significant gynecologic side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Very early medical abortion before confirmed intrauterine pregnancy.

Danish medical journal·2026
Same author

Correction: Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling.

Familial cancer·2026
Same author

Correction: A meta-analysis of previous falls and subsequent fracture risk in cohort studies.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Characterizing the timing and causes of death in community-acquired pneumonia.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026

Area of Science:

  • Pharmacology
  • Endocrinology
  • Bone Biology

Background:

  • Selective estrogen receptor modulators (SERMs) offer alternatives to hormone replacement therapy for postmenopausal bone loss.
  • Levormeloxifene was investigated for its potential to treat and prevent bone loss in postmenopausal women.

Purpose of the Study:

  • To review preclinical and clinical studies of levormeloxifene.
  • To discuss the reasons for its development's discontinuation.
  • To explore other SERMs and future perspectives.

Main Methods:

  • Review of preclinical animal models assessing bone turnover and bone loss.
  • Analysis of clinical studies in postmenopausal women evaluating bone mineral density and bone turnover.
  • Examination of adverse event data, particularly gynecologic events.

Related Experiment Videos

Main Results:

  • Levormeloxifene demonstrated efficacy in preventing bone loss and turnover in animal models.
  • Clinical studies showed levormeloxifene decreased bone turnover and increased bone mineral density comparable to hormone replacement therapy.
  • No dose-dependent effect was observed, and development ceased due to significant gynecologic adverse events.

Conclusions:

  • Levormeloxifene exhibited potential for treating postmenopausal bone loss but faced challenges.
  • The lack of a clear dose-response and safety concerns led to its discontinuation.
  • The review highlights the complexities in developing effective and safe SERMs.